Immunogenicity Risk Profile of Nanobodies.
Animals
Antibodies
/ blood
Camelids, New World
Cell Proliferation
Coculture Techniques
Cytokines
/ metabolism
Dendritic Cells
/ immunology
Humans
Membrane Glycoproteins
/ immunology
Receptor, ErbB-2
/ immunology
Receptors, Immunologic
/ immunology
Single-Domain Antibodies
/ administration & dosage
T-Lymphocytes
/ immunology
DC activation
T cell—DC interactions
anti drug antibodies
dendritic cells
immunogenicity
nanobody
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
11
2020
accepted:
15
02
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or Nanobodies, the recombinant single domain affinity reagents derived from heavy chain-only antibodies in camelids, are proven to possess a low immunogenicity risk profile, which will facilitate a growing number of Nanobodies to enter the clinic for therapeutic or
Identifiants
pubmed: 33767701
doi: 10.3389/fimmu.2021.632687
pmc: PMC7985456
doi:
Substances chimiques
Antibodies
0
Cytokines
0
MRC1 protein, human
0
Membrane Glycoproteins
0
Receptors, Immunologic
0
Single-Domain Antibodies
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
632687Informations de copyright
Copyright © 2021 Ackaert, Smiejkowska, Xavier, Sterckx, Denies, Stijlemans, Elkrim, Devoogdt, Caveliers, Lahoutte, Muyldermans, Breckpot and Keyaerts.
Déclaration de conflit d'intérêts
SD was employed by SD Analytics. ND, MK, and TL hold patents on the use of anti-HER2 and -MMR Nbs for the diagnosis and treatment of cancer and cardiovascular diseases. ND and TL are co-founder of, shareholder of and employed by or consultant for Precirix, a company that uses the anti-HER2 nanobody in radiotherapeutic applications. ND, MK, and TL are co-founder of Abscint who develops the anti-HER2 and anti-MMR Nb tracers for diagnostic purposes. ND has received funding from Boehringer-Ingelheim, Complix, Agenus, Confo Therapeutics, Roche, 121BIO, Agenus, Exevir, and Telix Pharma. MK, TL, ND, and CX have patents on Nb imaging and therapy. TL received honoraria from Precirix (consultant and board member), IBA (scientific advisor), and Institut des Radioéléments (IRE) (scientific advisor). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Nucl Med. 2001 Nov;42(11):1697-703
pubmed: 11696642
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
Trends Biotechnol. 2015 Jul;33(7):408-18
pubmed: 25931178
Trends Biotechnol. 2015 Jan;33(1):27-34
pubmed: 25488117
Science. 2009 Apr 17;324(5925):392-7
pubmed: 19286519
Expert Rev Clin Immunol. 2015;11 Suppl 1:S33-41
pubmed: 26395835
Mol Imaging Biol. 2019 Oct;21(5):898-906
pubmed: 30671739
Immunol Cell Biol. 2017 Mar;95(3):306-315
pubmed: 27713394
Nat Immunol. 2007 Nov;8(11):1207-16
pubmed: 17922016
J Clin Immunol. 2013 Oct;33(7):1192-203
pubmed: 23832582
Nat Biotechnol. 2015 Apr;33(4):334-6
pubmed: 25850051
Expert Rev Clin Pharmacol. 2011 Sep;4(5):623-31
pubmed: 22114889
N Engl J Med. 2019 Jan 24;380(4):335-346
pubmed: 30625070
J Nucl Med. 2013 May;54(5):776-84
pubmed: 23487015
Immunity. 2017 Sep 19;47(3):582-596.e6
pubmed: 28930664
Semin Cell Dev Biol. 2019 Feb;86:44-49
pubmed: 29448070
Annu Rev Immunol. 2018 Apr 26;36:695-715
pubmed: 29490163
Cancer Res. 2004 Apr 15;64(8):2853-7
pubmed: 15087403
Arthritis Res Ther. 2015 May 20;17:135
pubmed: 25994180
Cancer Lett. 2013 Jul 1;334(2):237-44
pubmed: 22902507
J Pharm Sci. 2009 Sep;98(9):3247-64
pubmed: 19569057
PLoS One. 2014 Jan 21;9(1):e86322
pubmed: 24466023
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
Clin Immunol. 2013 Dec;149(3):534-55
pubmed: 24263283
Gastroenterology. 2013 Oct;145(4):740-748.e8
pubmed: 23831050
Rev Argent Microbiol. 2015 Oct-Dec;47(4):368-79
pubmed: 26654700
J Biol Chem. 2009 Jan 30;284(5):3273-3284
pubmed: 19010777
FASEB J. 2011 Jul;25(7):2433-46
pubmed: 21478264
Sci Rep. 2018 May 21;8(1):7934
pubmed: 29784954
J Cardiovasc Transl Res. 2013 Jun;6(3):355-63
pubmed: 23307200
Cytokine. 1995 Jan;7(1):15-25
pubmed: 7538333
Clin Cancer Res. 2017 Nov 1;23(21):6616-6628
pubmed: 28751451
Nanomedicine (Lond). 2013 Jun;8(6):1013-26
pubmed: 23730699
J Exp Med. 2008 Nov 24;205(12):2839-50
pubmed: 18981237
Protein Cell. 2018 Jan;9(1):3-14
pubmed: 28271446
J Immunol Methods. 2004 Jun;289(1-2):1-16
pubmed: 15251407
Nat Immunol. 2007 Nov;8(11):1217-26
pubmed: 17922015
Science. 2006 Jan 6;311(5757):83-7
pubmed: 16322423
Nat Rev Drug Discov. 2019 Jul;18(7):485-487
pubmed: 31267082
MAbs. 2015;7(4):693-706
pubmed: 26018625
J Nucl Med. 2015 Aug;56(8):1265-71
pubmed: 26069306
Drug Discov Today. 2016 Jul;21(7):1076-113
pubmed: 27080147
Immunity. 2017 Dec 19;47(6):1051-1066.e12
pubmed: 29262348
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
J Immunotoxicol. 2014 Apr-Jun;11(2):99-109
pubmed: 23919460
Theranostics. 2019 Oct 15;9(25):7772-7791
pubmed: 31695800
Nat Biotechnol. 2011 Oct 13;29(10):870-3
pubmed: 21997623
Cell Death Dis. 2020 Apr 1;11(4):213
pubmed: 32238802
Cancer Chemother Pharmacol. 2015 May;75(5):887-95
pubmed: 25721064
Drug Discov Today. 2018 Dec;23(12):1996-2002
pubmed: 29890227
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
Curr Opin Drug Discov Devel. 2007 May;10(3):332-40
pubmed: 17554860